Bluebird Sickle Cell Gene Therapy Hangs In Balance
Company Probes Causes Of Blood Cancers
The company will likely have its answer in a matter of weeks, but a link to the vector would be a “worst-case scenario.”
You may also be interested in...
A resolution in a long-running patent dispute, expansion of coronavirus vaccine production, drug development trends over the past decade, hematological malignancies in a clinical trial, and the last instalment in the Scrip Asks series all feature in this week's podcast version of Scrip's Five Must-Know Things.
The sponsors of seven new drugs are set to find out this week whether the European Medicines Agency’s human medicines committee, the CHMP, will recommend pan-EU approval for their products. CHMP action is also expected regarding two potential combination therapies for COVID-19.